Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Here is the second part of the presentation on "Lung Cancer Highlights, 2011" by Dr. Jared Weiss. This section of his talk focuses on the striking story of the identification of the ALK rearrangement as a relevant target in lung cancer, along with an impressive treatment for this subgroup, and other new targets, such as ROS-1.
Below you'll find the audio and video versions of the podcast, as well as the transcript and figures.
Dr. Weiss Lung Cancer Highlights 2011, Pt 2 ALK and New Molecular Targets Audio Podcast
Dr. Weiss Lung Cancer Highlights 2011, Pt 2 ALK and New Molecular Targets Transcript
Dr. Weiss Lung Cancer Highlights 2011 Pt 2 ALK and New Molecular Targets Figs
The third and final part of Dr. Weiss's presentation will focus on advances for broader populations: smokers and the elderly. He'll cover the lung cancer screening trial known as the NLST, as well as an influential presentation of single agent vs. doublet chemotherapy in elderly patients with advanced NSCLC. Look for that here very soon.
Thanks again to LUNGevity Foundation for their sponsorship of this work with us, making this content possible.
Please feel free to offer comments and raise questions in our
discussion forums.
A Brief Tornado. I love the analogy Dr. Antonoff gave us to describe her presentation. I felt it earlier too and am looking forward to going back for deeper dive.
Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".
While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".
I hope any...
My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.
Here's the webinar on YouTube. It begins with the agenda. Note the link is a playlist, which will be populated with shorts from the webinar on specific topics
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.